0 iTBS brain stimulation reduces spasticity in spinal cord injury patients
A new study has demonstrated the potential of excitatory intermittent theta burst stimulation (iTBS) for reducing spasticity in patients with spinal cord injury.
Browsing: Movement disorders
0 Parkinson’s is partly an autoimmune disease, new study states
Researchers have found the first evidence that autoimmunity plays a role in Parkinson’s disease, showing that T cells recognize α-synuclein peptides.
0 Huntington’s pathology alleviated by CRISPR/Cas9 gene editing
An international research team have shown that gene editing reverses Huntington’s symptoms without off-target effects in a mouse model.
0 Repurposing of malaria drug to halt ALS disease progression
Researchers discover that the drug, pyrimethamine, may reduce disease progression in patients with inherited amyotrophic lateral sclerosis (ALS).
0 Gene-editing technology allows scientists to measure alpha-synuclein levels
Researchers from the University of Central Florida hope to use the CRISPR Cas9 method to screen drugs for Parkinson’s disease.
0 NCTalks with Alberto Espay: a biomarker-driven approach to subtyping Parkinson’s disease
Could this new approach drive Parkinson’s disease into the age of personalized medicine?
0 NCTalks with Regina Katzenschlager: apomorphine as a treatment for Parkinson’s disease
We caught up with Regina Katzenschlager at AAN 2017, whose research into the use of apomorphine for Parkinson’s disease was highlighted at the conference as one to watch.
0 Essential tremor patient successfully treated with MR-guided focused ultrasound treatment
A patient with bilateral essential tremor has recently become the first patient in Pennsylvania (USA) to be successfully treated with a new, non-invasive, MR-guided focused ultrasound treatment.
0 The future of neuromodulation: an interview with Timothy Deer, President of the International Neuromodulation Society
Dr Deer discusses his career highlights, most memorable patient cases, and looks ahead at future challenges and trends in the field of neuromodulation.
0 AAN17: Phase III study reports the positive effects of an “old” drug for the treatment of advanced Parkinson’s disease
Study participants receiving apomorphine also gave their treatment higher effectiveness scores than those who received the placebo.